2005至2019年多发性骨髓瘤随机试验中的时间-事件替代终点:一项替代性分析
该系统综述纳入2005至2019年间发表的88项多发性骨髓瘤随机对照试验,评估无进展生存期(PFS)等时间-事件终点作为总生存期(OS)替代终点的强度。67项(76%)试验以PFS为主要或共同主要终点,仅1项试验说明进展为生化进展还是临床进展。PFS与OS相关性弱(0.62,95%CI 0.38-0.78),PFS是MM中OS的劣质替代终点。
要点
- 88项随机试验中67项(76%)以PFS为主要或共同主要终点。
- PFS与OS相关性弱(0.62,95%CI 0.38-0.78),OS变异的39%归因于PFS变异。
- 仅1项试验说明疾病进展为生化进展还是临床进展。
核心结论
- PFS和进展特征在多发性骨髓瘤试验中描述不佳,且PFS是MM中OS的劣质替代终点。
研究设计与样本
- 系统综述,纳入2005至2019年间发表的88项多发性骨髓瘤随机对照试验,使用PFS或其他时间-事件终点,采用线性回归和Pearson相关评估OS风险比与PFS风险比之间的关联,以决定系数评估替代强度。
主要发现
- 88项随机对照试验中67项(76%)以PFS为主要或共同主要终点。
- 仅1项试验说明疾病进展为生化进展还是临床进展。
- OS变异的39%归因于PFS变异,PFS与OS相关性弱(0.62,95%CI 0.38-0.78)。
- 新诊断MM中,OS变异的43%归因于PFS变化,PFS与OS相关性弱(0.65,95%CI 0.30-0.84)。
- 复发/难治MM中,OS变异的58%归因于PFS变化,PFS与OS相关性中等(0.76,95%CI 0.42-0.91)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review characterises all published randomised controlled trials (RCTs) in MM using PFS or other TTE end-points between 2005 and 2019 and assesses strength of surrogacy of PFS for overall survival (OS). The association between OS hazard ratios (HRs) and PFS HRs was evaluated with linear regression, and the coefficient of determination with Pearson's correlation. We identified 88 RCTs of which 67 (76%) used PFS as the primary/co-primary end-point. One trial indicated whether progression was biochemical or clinical. Of the variance in OS, 39% was due to variance in PFS. Correlation between PFS and OS was weak (0.62, 95% confidence interval [CI] 0.38-0.78). In newly diagnosed MM, 43% of the variance in OS was due to changes in PFS. The correlation between PFS and OS was weak (0.65, 95% CI 0.30-0.84). In relapsed/refractory MM, 58% of the variance in OS was due to changes in PFS. Correlation between PFS and OS was medium (0.76, 95% CI 0.42-0.91). We demonstrate that PFS and progression characteristics are characterised poorly in MM trials and that PFS is a poor surrogate for OS in MM.
引用
- Etekal T, Koehn K, Sborov DW, et al. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2022. PMID: 36495317. doi:10.1111/bjh.18568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。